Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 19 years old or above Koreans living in Korea~2. Patients with uncontrolled essential hypertension at screening time(Visit 1)~   * Naïve: 160 mmHg ≤ sitSBP \< 200 mmHg~  * Use antihypertensive drugs:140 mmHg ≤ sitSBP \< 200 mmHg~3. Patients with uncontrolled hypertension after Telmisartan/Amlodipine 40/5mg treatment for 6 weeks at randomization(Visit 2)~   - 140 mmHg ≤ sitSBP \< 200 mmHg~4. Patients who agreed to participate in the trial~Exclusion Criteria:~1. Test results showing the following values at screening time(Visit 1)~   * The change of mean sitSBP ≥ 20 mmHg or sitDBP ≥ 10 mmHg on target arm between 1st and 2nd measurement~  * screening time(Visit 1), time of randomization(Visit 2): sitDBP ≥ 120 mmHg~2. Patients with secondary blood pressure or suspected of secondary blood pressure (for example,aortic coarctation, primary aldosteronism, renal artery stenosis, pheochromocytoma)~3. -Patients with congestive heart failure(NYHA class III\~IV)~   * Patients with unstable angina or myocardial infarction or valvular heart disease within 6 months prior to study entry~  * Patients who have severe ventricular tachycardia, atrial fibrillation, atrial flutter or clinically significant arrhythmia~4. Patients who have history of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months prior to study entry~5. Type I Diabets Mellitus or Type II Diabetes Mellitus with HbA1c \> 9%~6. Patients who have history of severe or malignant retinopathy within 6 months prior to study entry~7. Patients who suspected of Renal dysfunction that may affect the absorption, distribution, metabolism or excretion (Serum Creatinine :\> 2mg/dL ), gastrointestinal, haematological, liver disease (AST or ALT \> 2.5 times of upper limit of normal range)~8. Patients who should be administered antihypertensive drugs other than clinical trial medication(Diuretics, β-blockers, ACE inhibitors, Angiotensin II Receptor Blocker, Calcium Channel Blockers, α-blockers, Renin Inhibitors, Vasodilators)~9. Patients who should be administered medications prohibited for concomitant use during study period~10. Patients who are dependent on drugs or alcohol~11. Patients with surgical and medical disease that may affect the absorption, distribution, metabolism or excretion~12. Patients with hypersensitivity to the components of investigational drug.~13. Patients with hypersensitivity to Sulfonamide~14. Patients with anuria~15. Patients with hypercalcemia, hyponatremia/hypokalemia~16. Patients with Addison's disease~17. Patients who have hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption~18. Patients with any chronic or accute inflammation disease needed to chronic inflammation therapy~19. History of malignant tumor including leukemia, lymphoma within 5 years~20. Patients taking other clinical trial drugs within 30 days from the time of visit for screening~21. Pregnancy, breast-feeding, or child-bearing potential Patients~22. Patients who are judged unsuitable to participate in this study by investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telmisartan/Amlodipine+Hydrochlorothiazide (Type: EXPERIMENTAL): Telmisartan/Amlodipine combination drug and Hydrochlorothiazide
- Telmisartan/Amlodipine (Type: ACTIVE_COMPARATOR): Telmisartan/Amlodipine combination drug and Placebo for Hydrochlorothiazide

Based on this trial design, predict the completion outcome and termination type (if applicable).